Company intelligence / Profile preview

Chansu Vascular Technologies

Sunnyvale, California, United Statesvascularnews.com ↗

Ownership: Private
Development stage: Other

Overview

Chansu Vascular Technologies has developed novel everolimus drug-coated balloons for use in peripheral and coronary interventions. The company initiated first-in-human clinical trials for its peripheral DCB in early 2022, with successful initial cases reported. The DCBs are designed to deliver sustained anti-restenotic efficacy without permanent implants, leveraging everolimus’s established safety profile from stent applications.

Therapeutic areas: Cardiovascular
Modalities: DeviceDrug-coated balloonSmall molecule
Industry: Therapeutic Medical Devices

Partnerships

Cardiovascular Systems Inc. (“CSI”): Milestone-based financing partnership with an exclusive acquisition option upon achievement of technical/clinical milestones by CVT

Beyond the preview

Go deeper on Chansu Vascular Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chansu Vascular Technologies.

Explore the full profile